Pipeline

Active

Indication

FORMULATION

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

Transdermal Synthetic CBD

Parkinson’s Disease

Transdermal Dronabinol (THC)

Parkinson’s Disease
Potential 505(b)2 pathway
  • Targeting an accelerated 505(b)2 registration pathway allows Sponsor to reference existing clinical safety and efficacy data – reducing risk, cost, and time to FDA approval.
  • Potential to leverage pipeline for investigation into treating other serious neurological diseases.
Pikefull
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.